How long is it safe to take Ozempic?

There is no FDA-defined maximum duration for Ozempic. The longest randomized exposure data on the semaglutide molecule is the SELECT cardiovascular outcomes trial (median 3.3 years at 2.4 mg weekly) and SUSTAIN-6 (median 2.1 years at 0.5 or 1.0 mg). The closest within-class analog with longer follow-up is the LEADER liraglutide trial at median 3.8 years. Across all three trials, the safety profile after multi-year exposure was qualitatively the same as the early-exposure profile — no novel adverse-event class emerged at year 3 or 4 that was absent at year 1. Beyond 5 years there is no randomized data on semaglutide and only post-marketing surveillance (FAERS) data. Most prescribers and the FDA treat Ozempic as a chronic medication akin to a statin or antihypertensive — taken for years, monitored periodically, discontinued only for adverse events or pregnancy.

Does the side-effect rate get worse the longer you take Ozempic?

No — the GI adverse-event rate is highest during the titration period (weeks 1-16) and falls substantially during the maintenance phase. SELECT reported that gastrointestinal adverse events leading to discontinuation occurred in 4.3% of semaglutide-treated patients vs 1.5% on placebo over the median 3.3-year follow-up, with most discontinuations happening in the first 6-12 months. The serious adverse events that remain under post-marketing surveillance (pancreatitis, gallbladder disease, acute kidney injury during dehydration, NAION signal) do not appear to accelerate with longer exposure — they appear to be event-driven rather than cumulative-dose-driven.

What about the thyroid cancer boxed warning — is that real?

The boxed warning is based on rodent carcinogenicity studies showing dose-dependent thyroid C-cell tumors in rats and mice treated with GLP-1 receptor agonists. Whether the rodent finding translates to humans has been an active monitoring question since liraglutide's 2010 FDA approval. After 14+ years of human exposure to GLP-1 RAs in the United States and tens of millions of patient-years, the post-marketing surveillance signal for medullary thyroid carcinoma (the C-cell-derived cancer the rodent finding predicts) has not been confirmed. The boxed warning remains, and the label contraindicates use in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Calcitonin screening is not routinely recommended.

What is the NAION signal and should I be worried?

Nonarteritic anterior ischemic optic neuropathy (NAION) is a sudden, painless loss of vision in one eye caused by interrupted blood flow to the optic nerve head. Hathaway and colleagues (2024 JAMA Ophthalmology, PMID 38958939) reported a matched-cohort retrospective analysis from Mass Eye and Ear showing higher NAION incidence in patients prescribed semaglutide vs non-GLP-1 comparators (HR 4.28 in T2D, HR 7.64 in obesity). Replication studies (PMIDs 39480403, 39976950 and others) have been mixed; some find an elevated risk, others do not, and absolute event rates remain rare. The FDA and EMA are both monitoring the signal; it is not yet confirmed as a causal association and Ozempic labeling has not been updated to add NAION as of May 2026. The honest take: report any sudden one-eye vision change to your prescriber immediately, but the absolute risk remains low and the cardiovascular benefit of semaglutide in SELECT and SUSTAIN-6 is well-established.

Is Ozempic safe to take during pregnancy?

No. The Ozempic label instructs that semaglutide be discontinued at least 2 months before a planned pregnancy because of the long elimination half-life (~1 week, meaning the drug is detectable in plasma for roughly 5-7 weeks after the last dose). Animal reproduction studies showed adverse developmental effects at clinically relevant exposures. Human pregnancy data are limited and have not been adequate to assess teratogenicity. Patients of reproductive potential who become pregnant unexpectedly while on Ozempic should contact their prescriber to discuss discontinuation and prenatal monitoring; the manufacturer maintains a pregnancy outcome registry that collects data on these exposures.

Do I need extra monitoring labs while on long-term Ozempic?

Standard chronic-medication monitoring applies. The Ozempic label does not mandate any specific schedule of labs; in T2D the practical routine is HbA1c every 3 months until target then every 6 months, with renal function (eGFR, urine albumin) annually given the FLOW data on kidney outcomes and the AKI warning during dehydration. Lipase and amylase are not routinely checked for asymptomatic patients — they're drawn if pancreatitis is clinically suspected (severe abdominal pain). Calcitonin screening is not recommended. Vision changes warrant prompt ophthalmologic evaluation given the unresolved NAION signal. There is no required monitoring frequency that increases with years on therapy.

Ozempic Long-Term Side Effects: Chronic-Exposure Evidence Review

3.3 yearsSELECT median semaglutide exposure — longest randomized

This long-term safety review is part of Weight Loss Rankings’ living editorial database — 300+ research articles and 190+ clinically-reviewed GLP-1 telehealth providers, sourced only from FDA prescribing information on DailyMed and peer-reviewed PubMed literature.

Most coverage of Ozempic side effects answers the acute question: will the first month make me nauseous? This review answers the chronic question instead. What do we actually know about taking Ozempic for three, five, seven, or more years? The answer is anchored to three randomized trials that crossed the multi-year threshold, one large post-marketing pharmacovigilance database, and the close-cousin liraglutide data from before semaglutide existed as a marketed drug.

The honest answer

The longest-followup randomized data on the semaglutide molecule is SELECT (median 3.3 years at 2.4 mg) and SUSTAIN-6 (median 2.1 years at 0.5-1.0 mg). The cardiovascular safety record is well-established. Rare but serious concerns — pancreatitis, gallbladder disease, kidney injury during dehydration, and the NAION signal from Hathaway 2024 — remain under active post-marketing surveillance. The thyroid C-cell tumor finding from rodent carcinogenicity studies has not been confirmed in humans across 14+ years of human GLP-1 exposure.

How long is “long-term” for Ozempic? The SELECT 3.3-year benchmark

Ozempic (semaglutide injection) was FDA-approved in December 2017 for type 2 diabetes glycemic control, with a cardiovascular risk-reduction indication added based on the SUSTAIN-6 trial. By May 2026, that is roughly 8.5 years of marketed use and tens of millions of patient-years of post-marketing exposure. The molecule itself entered human trials in 2008 (Phase 1) and started Phase 3 in 2013 with SUSTAIN-1, so the human-exposure history of semaglutide as a research compound is closer to 18 years. The within-class predecessor liraglutide (Victoza) has been FDA- approved since 2010 and shares the GLP-1 receptor agonist side-effect class.

The randomized trials anchor what we actually know about chronic exposure:

SELECT (Lincoff 2023, NEJM): median follow-up 39.8 months — 3.3 years — on semaglutide 2.4 mg weekly in 17,604 adults with established CV disease and overweight/obesity without diabetes. Longest randomized exposure data on the semaglutide molecule at any dose.^[2]
SUSTAIN-6 (Marso 2016, NEJM): median follow-up 2.1 years on semaglutide 0.5 or 1.0 mg weekly in 3,297 adults with T2D at high CV risk. Longest randomized exposure data at Ozempic-label doses.^[1]
FLOW (Perkovic 2024, NEJM): semaglutide 1.0 mg weekly in 3,533 adults with T2D and chronic kidney disease; stopped early at planned interim analysis for efficacy, with a shorter average follow-up than SELECT.^[4]
LEADER (Marso 2016, NEJM): median follow-up 3.8 years on liraglutide in 9,340 adults with T2D at high CV risk. Not semaglutide, but the closest within-class analog — same GLP-1 receptor agonist scaffold, same side-effect class. Used here for the very-long-term safety signal that semaglutide itself has not yet matured into.^[3]

Above five years, the only signal we have for semaglutide is post-marketing surveillance via the FDA Adverse Event Reporting System (FAERS), the EU EudraVigilance database, and large real- world EHR cohorts. There is no published 7-year or 10-year randomized data on semaglutide as of May 2026. Patients and prescribers making 10-year decisions are making them on signals, not on randomized evidence.

Cardiovascular safety after 2-4 years (SUSTAIN-6, SELECT, LEADER analog)

The cardiovascular safety record on multi-year semaglutide exposure is unusually clean for a chronic medication. SUSTAIN-6 was originally designed to show non-inferiority for the primary MACE composite (cardiovascular death, nonfatal MI, nonfatal stroke) in T2D patients at high CV risk. It cleared non-inferiority and then continued to superiority: hazard ratio 0.74 (95% CI 0.58-0.95, p<0.001 for non-inferiority, p=0.02 for superiority) over a median 2.1 years.^[1]

SELECT extended this reading into the obesity-without-diabetes population at the higher 2.4 mg weekly dose. Over a median 3.3 years, the MACE composite occurred in 6.5% of the semaglutide group versus 8.0% on placebo (HR 0.80, 95% CI 0.72-0.90, p<0.001). The relative-risk reduction was consistent across prespecified subgroups, and overall cardiovascular mortality also favored semaglutide.^[2]

LEADER, the closest within-class analog with longer follow-up, showed liraglutide reduced MACE in T2D patients at high CV risk (HR 0.87, 95% CI 0.78-0.97) over a median 3.8 years. Critically, the safety signals across LEADER — the ones still being discussed today — remained event-driven rather than cumulative-dose-driven across the 3.8-year exposure. Pancreatitis, thyroid neoplasms, and renal events did not accelerate with duration.^[3]

Magnitude comparison

Median randomized exposure durations for the three trials that anchor the long-term semaglutide safety conversation, plus the LEADER liraglutide analog. SELECT's 3.3-year median is the longest randomized exposure data set on the semaglutide molecule at any dose; LEADER's 3.8-year median is the longest randomized data within the GLP-1 receptor agonist class.^[1]^[2]^[3]^[4]

LEADER (liraglutide) — median follow-up3.8 years
within-class analog; longest GLP-1 RA randomized data
SELECT (semaglutide 2.4 mg) — median follow-up3.3 years
longest randomized semaglutide exposure at any dose
SUSTAIN-6 (semaglutide 0.5 or 1.0 mg) — median follow-up2.1 years
longest randomized data at Ozempic-label doses
FLOW (semaglutide 1.0 mg in T2D + CKD)3.4 years
stopped early for efficacy; mean ~3.4 yr at termination

Pancreatitis: rates from pooled trials and FAERS

Acute pancreatitis has been the canonical GLP-1-class safety question since the exenatide era. The Ozempic label carries a Warnings and Precautions section on acute pancreatitis directing prompt discontinuation if pancreatitis is suspected. In randomized trials, pancreatitis events are rare and not statistically distinguishable from placebo:

SUSTAIN-6: acute pancreatitis confirmed in 0.27% of semaglutide-treated patients vs 0.46% on placebo over median 2.1 years. Not elevated.^[1]
SELECT: acute pancreatitis in 0.2% on semaglutide vs 0.3% on placebo over median 3.3 years. Not elevated.^[2]
LEADER (liraglutide, 3.8-year exposure): acute pancreatitis in 0.4% on liraglutide vs 0.5% on placebo. Not elevated.^[3]

The FAERS post-marketing picture is more complicated because spontaneous reports are subject to reporting bias and notoriety effects (high-profile drugs get reported more). Pooled disproportionality analyses of GLP-1 RAs in FAERS have shown elevated reporting odds ratios for pancreatitis — consistent with the labeling warning. The contemporary interpretation is that pancreatitis is a real but rare adverse event of GLP-1 receptor agonism, with a chronic-exposure rate that does not appear to escalate over multi-year use. Prior history of pancreatitis is the strongest individual predictor.

Gallbladder disease: rapid weight loss and cholesterol gallstone risk

Gallbladder disease is the clearest confirmed long-term safety signal across the GLP-1 receptor agonist class. He and colleagues (2022 JAMA Internal Medicine) pooled 76 randomized trials (n=103,371) and reported a relative risk of 1.37 (95% CI 1.23- 1.52) for the composite of cholelithiasis, cholecystitis, and biliary disease in patients on GLP-1 RAs versus placebo. The signal was driven more strongly by higher doses, longer durations, and weight-loss indications than by glycemic-control indications.^[6]

The mechanism is well-understood and not a mystery drug effect. Rapid weight loss of any cause — surgical, dietary, or pharmacological — raises cholesterol saturation of bile and slows gallbladder motility, both of which promote cholesterol gallstone formation. Semaglutide’s magnitude of weight loss at the 2.4 mg dose (STEP-1: -14.9% body weight over 68 weeks) puts patients in the rapid-weight-loss risk window that bariatric surgery literature has been describing for decades. The FAERS case series from Woronow and colleagues (2022) showing post-marketing cholecystitis reports across the GLP-1 RA class supported the addition of acute gallbladder disease to the GLP-1 RA class labeling.^[7]^[9]

Clinically: right upper quadrant pain, especially after fatty meals, warrants prompt evaluation in any patient on multi-year GLP-1 RA therapy. Routine prophylactic cholecystectomy is not recommended; ursodiol prophylaxis during the rapid-weight-loss phase has been studied in bariatric populations but is not standard practice for GLP-1 RA users.

Kidney injury: acute versus chronic — what the FLOW trial showed

The kidney story has two halves that point in opposite directions, and both halves matter for long-term users.

Acute kidney injury (AKI) during dehydration. The Ozempic label warns that AKI has been reported in patients treated with semaglutide, sometimes requiring hemodialysis, and sometimes occurring in patients without known underlying renal disease. The mechanism is well-characterized: GLP-1 RA-driven nausea/vomiting/diarrhea produces volume contraction; volume contraction in a kidney already exposed to RAAS-axis medications or NSAIDs is a setup for prerenal AKI. The acute risk is front-loaded into the titration period, not a chronic-exposure risk.

Chronic kidney protection. Pointing the other direction, the FLOW trial (Perkovic 2024 NEJM) randomized 3,533 adults with T2D plus established chronic kidney disease to semaglutide 1.0 mg weekly vs placebo. The trial was stopped early at its planned interim analysis for efficacy: the primary composite kidney outcome (major kidney disease events) occurred at hazard ratio 0.76 (95% CI 0.66-0.88) in favor of semaglutide. Long-term semaglutide exposure in T2D + CKD protects kidney function on the same time horizon that the acute-AKI warning sits.^[4]

The synthesis: acute AKI from dehydration is a real but largely preventable event — manage GI losses, hold the drug during acute illness with significant vomiting or diarrhea, hold during major surgical procedures, monitor renal function annually. The long-term renal trajectory in patients with diabetic kidney disease appears protective. The Ozempic label does not contraindicate use in CKD; it warns about volume status during intercurrent illness.

NAION signal (Hathaway 2024) — what we know

In July 2024, Hathaway and colleagues at Mass Eye and Ear published a matched retrospective cohort analysis in JAMA Ophthalmology reporting elevated incidence of nonarteritic anterior ischemic optic neuropathy (NAION) in patients prescribed semaglutide compared with matched non-GLP-1 controls. In the T2D cohort the hazard ratio was 4.28 (95% CI 1.62-11.29); in the overweight/obesity cohort the hazard ratio was 7.64 (95% CI 2.21-26.36). Absolute event rates remained low.^[5]

NAION is a sudden, painless, monocular loss of vision caused by interrupted blood flow to the optic nerve head. It is uncommon in the general population (incidence roughly 2-10 per 100,000 per year) and most often associated with crowded optic disc anatomy, hypertension, diabetes, hyperlipidemia, and sleep apnea. The proposed mechanism for a semaglutide association is not established — candidate hypotheses include rapid glycemic-shift hemodynamic effects on the optic nerve head and weight-loss-mediated changes in optic-nerve perfusion pressure.

Replication studies have been mixed. Some matched-cohort analyses in different data sets reported elevated risk; others did not find a statistically significant signal. As of May 2026, the FDA and EMA are both monitoring the signal but neither agency has added NAION to the Ozempic or Wegovy labels as a confirmed adverse reaction.

The honest clinical take: report any sudden one-eye vision change to your prescriber immediately and seek same-day ophthalmologic evaluation. The absolute risk remains low; the cardiovascular benefit of semaglutide is well-established. The signal warrants vigilance, not panic.

Thyroid C-cell tumors: rodent finding, 14+ years of human data

Every GLP-1 receptor agonist on the US market carries an FDA boxed warning for thyroid C-cell tumors. The warning is anchored to dose- and duration-dependent thyroid C-cell tumors observed in rats and mice treated with GLP-1 RAs during preclinical carcinogenicity studies. The label contraindicates use in patients with a personal or family history of medullary thyroid carcinoma (the C-cell-derived cancer the rodent finding predicts) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Whether the rodent finding translates to humans has been the active monitoring question since liraglutide’s 2010 FDA approval. The mechanistic concern is real — rodent thyroid C cells express GLP-1 receptors at higher density than human thyroid C cells, which is part of why the rodent model is considered a worst-case predictor rather than a direct human translation. After 14+ years of human exposure to GLP-1 RAs in the United States and tens of millions of patient-years across liraglutide, exenatide, dulaglutide, and semaglutide, the post-marketing surveillance signal for medullary thyroid carcinoma in humans has not been confirmed.

The boxed warning remains in place. Calcitonin screening is not routinely recommended by the Ozempic label or by professional societies, because the negative-predictive value in low-prevalence populations is poor and false positives generate unnecessary thyroid biopsies. Patients with personal or family history of MTC or MEN 2 should not take Ozempic.

Mood, depression, and suicidality monitoring

In July 2023, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee opened a review of spontaneous reports of suicidal ideation and self-injury in patients on GLP-1 RAs. The review concluded in April 2024 that the available evidence did not support a causal association; the Ozempic and Wegovy labels were not amended to add suicidality as a confirmed adverse reaction. The FDA reached a similar conclusion after reviewing FAERS reports.

The strongest counter-signal comes from Wang and colleagues (2024 Nature Medicine), who studied 240,618 overweight/obesity patients and 1,589,855 T2D patients in a real-world EHR cohort and found semaglutide associated with lower rates of suicidal ideation versus non-GLP-1 anti-obesity comparators: hazard ratio 0.27 (95% CI 0.20-0.36) in the obesity cohort and HR 0.36 (95% CI 0.32-0.41) in the T2D cohort. Limitations include the observational design, residual confounding, and the comparator choice (non-GLP-1 anti-obesity medications, not no medication).^[8]

The current Ozempic label retains a post-marketing surveillance mention of suicidal behavior and ideation in Section 6.2 but does not list these as confirmed adverse reactions. Clinically: patients with a personal history of severe depression or suicidal ideation should still discuss the risk-benefit balance with their prescriber, and any new or worsening mood symptoms while on therapy warrant prompt evaluation. The signal has not converted into a confirmed causal association after two years of regulatory review and one large real-world cohort study, but the regulatory watch continues. For a deeper breakdown of this evidence base, see the dedicated GLP-1 depression and suicidality evidence review.

Pregnancy and fertility: the 2-month washout rule

The Ozempic label instructs that semaglutide be discontinued at least 2 months before a planned pregnancy because of the long elimination half-life of the molecule (~1 week, meaning the drug remains detectable in plasma for roughly 5-7 weeks after the last dose). Animal reproduction studies in rats, rabbits, and cynomolgus monkeys showed adverse developmental effects at clinically relevant exposures — embryolethality, teratogenicity, and growth alterations. Human pregnancy data are limited and not adequate to assess the teratogenic potential of semaglutide.

The 2-month-washout instruction has a real clinical implication for patients of reproductive potential who are using Ozempic for chronic weight management or T2D and are considering pregnancy. The practical sequence is: discuss family planning at the start of Ozempic therapy; use reliable contraception while on therapy; discontinue Ozempic and switch to a pregnancy-safe alternative for glycemic control or weight management at least 8 weeks before intended conception. Patients who become pregnant unexpectedly while on Ozempic should contact their prescriber immediately to discuss discontinuation and prenatal monitoring. Novo Nordisk maintains a pregnancy outcome registry that collects exposure data on these cases.

A separate fertility question has emerged in the popular press about whether GLP-1-mediated weight loss restores ovulation in women with anovulation related to obesity or PCOS — sometimes called the “Ozempic baby” phenomenon. The mechanism is straightforward: weight loss restores hypothalamic- pituitary-ovarian axis function in women whose anovulation was driven by adiposity. There is no signal that semaglutide itself is a fertility drug; rather, the weight-loss effect produces a downstream fertility consequence in patients who were anovulatory due to obesity. This is part of why the 2-month washout matters: women whose cycles return on Ozempic may not realize they have regained fertility.

What happens when you stop after years on Ozempic

Weight regain after discontinuation is the most consistently observed long-term-exposure outcome and the one most patients ask about. The STEP 4 trial (Rubino 2021 JAMA) randomized patients who had completed a 20-week semaglutide 2.4 mg titration to either continued semaglutide or a switch to placebo for an additional 48 weeks. The continued-semaglutide group lost an additional 7.9% body weight from week 20 onward; the placebo-switch group regained 6.9% body weight from week 20 onward. Net difference: roughly 15 percentage points of body weight between continued and discontinued.^[10]

This is consistent with the broader obesity-pharmacotherapy literature. Appetite, satiety signaling, gastric emptying rate, and energy-expenditure adaptations all reverse when the GLP-1 receptor agonist is withdrawn, because the underlying physiological state of obesity has not changed — only its pharmacological suppression has. The contemporary framing is that obesity, like hypertension, is a chronic disease whose treatment is required indefinitely to maintain the treatment effect. This is the strongest argument for thinking about Ozempic and Wegovy as chronic-exposure medications.

Cardiovascular benefit also wanes after discontinuation in the way you would expect from a drug whose mechanism depends on continued receptor engagement. The MACE-reduction effect seen in SUSTAIN-6 and SELECT was measured in patients continuously on therapy. There is no published evidence that the cardiovascular benefit persists after discontinuation.

What we still don’t know — the very long-term (10+ years)

Five questions remain genuinely open as of May 2026:

10-year-plus randomized exposure data. No such data exists for semaglutide. The longest randomized exposure on any GLP-1 receptor agonist is LEADER’s 3.8-year median on liraglutide; SELECT’s 3.3-year median is the longest on semaglutide itself. Extension studies and ongoing surveillance will close some of this gap but will not produce randomized 10-year data in this decade.
Cumulative-dose adverse-event risk. Whether rare events — pancreatitis, cholangitis, severe NAION — cluster at specific cumulative-dose thresholds (e.g., year 5 or year 7) or remain event-driven at constant rates is not knowable from the trials we have.
NAION resolution. The Hathaway 2024 signal either replicates and gets added to labeling, or does not replicate and gets retired. As of May 2026, the regulatory posture is monitoring without label change. The next 12-24 months of replication studies and pharmacovigilance updates will resolve this.
Pregnancy and developmental safety. The Ozempic pregnancy registry will produce exposure-outcome data over the next 5+ years; until then, the 2-month-washout instruction stands and human teratogenicity data remain inadequate.
Bone density and sarcopenia. Multi-year GLP-1 RA-driven weight loss produces lean-mass loss alongside fat-mass loss. Whether this translates into measurable late- life sarcopenia, fracture risk, or functional decline is an active research question and one of the reasons resistance training is recommended alongside GLP-1 therapy.

For the acute and titration-period side effects (the early- exposure question), see the GLP-1 side effects: what the trials actually showed review and the interactive GLP-1 side effect timeline tool. For the broader Q&A landscape of patient concerns, see GLP-1 side effect questions answered.

Bottom line

Longest randomized data is 3.3 years (SELECT). SUSTAIN-6 (2.1 yr at Ozempic doses) and the LEADER liraglutide analog (3.8 yr) round out the multi-year evidence base. Beyond 5 years, we have FAERS post-marketing surveillance rather than randomized data.
Cardiovascular safety is established. SUSTAIN-6 HR 0.74; SELECT HR 0.80. Both highly significant. FLOW added a 24% relative reduction in kidney composite outcomes in T2D + CKD.
Gallbladder is the confirmed chronic-exposure signal. He 2022 meta-analysis: relative risk 1.37 for cholelithiasis/cholecystitis. Driven mostly by rapid weight loss, higher doses, longer durations.
NAION is the open question. Hathaway 2024 flagged the signal; replications are mixed; FDA and EMA are monitoring without label change. Report sudden one-eye vision loss immediately.
Thyroid C-cell warning persists but is unconfirmed in humans after 14+ years of GLP-1 RA exposure. Contraindicated in personal or family MTC or MEN 2 history.
Suicidality signal has not survived controlled analysis. EMA July 2024 review found no causal association; Wang 2024 found lower rates in semaglutide users. Surveillance continues.
Pregnancy: discontinue 2 months before conception. Animal reproductive toxicity at clinically relevant exposures; human data limited.
Stopping = regaining. STEP 4 randomized continuation vs withdrawal: 15-percentage-point body-weight delta. Obesity behaves like a chronic disease; the treatment effect requires continued treatment.

Frequently asked questions

GLP-1 side effects: what the trials actually showed — acute and titration-period side effects, pooled rates from STEP, SUSTAIN, and SURMOUNT.
GLP-1 side effect questions answered — Q&A landscape covering the most common patient questions about GLP-1 safety.
GLP-1 depression and suicidality evidence review — the deeper breakdown of the EMA PRAC review, the Wang 2024 Nat Med cohort, and the FAERS signal.
What SELECT showed about semaglutide and heart attack risk — the 3.3-year follow-up CV outcomes trial that anchors the long-term Wegovy/semaglutide story.
FLOW trial: semaglutide and chronic kidney disease — the kidney-protection counterpart to the acute-AKI warning.
Wegovy vs Ozempic: same molecule, different FDA approvals — the molecule-identity comparison; relevant because long-term semaglutide safety data is shared across the two labels.
GLP-1 side effect timeline tool — interactive titration-period and chronic-exposure side-effect visualizer.
Ozempic drug profile — full label, dose ladder, side-effect rates, and provider availability.

References

1.Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). Once-weekly semaglutide 0.5 or 1.0 mg reduced the primary composite of cardiovascular death, nonfatal MI, or nonfatal stroke (HR 0.74, 95% CI 0.58-0.95) over a median 2.1 years of follow-up in 3,297 adults with T2D at high CV risk. Foundational long-term safety + efficacy data for the Ozempic label. N Engl J Med. 2016. PMID: 27633186.
2.Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). Median 39.8 months (3.3 years) of follow-up on semaglutide 2.4 mg weekly in 17,604 adults with established CV disease and overweight/obesity but without diabetes. Primary MACE composite HR 0.80 (95% CI 0.72-0.90, p<0.001). The longest randomized exposure data set on the semaglutide molecule at any dose. N Engl J Med. 2023. PMID: 37952131.
3.Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee and LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). Median 3.8 years of follow-up on liraglutide in 9,340 adults with T2D at high CV risk. Primary MACE composite HR 0.87 (95% CI 0.78-0.97). Closest within-class very-long-term analog for the semaglutide molecule (same GLP-1 receptor agonist scaffold, same side-effect class). N Engl J Med. 2016. PMID: 27295427.
4.Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R; FLOW Trial Committees and Investigators. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). Once-weekly semaglutide 1.0 mg in T2D + CKD; stopped early for efficacy at planned interim analysis. Primary composite kidney outcome HR 0.76 (95% CI 0.66-0.88). Critical chronic-exposure kidney-safety data: the trial that the long-term renal narrative now centers on. N Engl J Med. 2024. PMID: 38785209.
5.Hathaway JT, Shah MP, Hathaway DB, Zekavat SM, Krasniqi D, Gittinger JW Jr, Cestari D, Mallery R, Abbasi B, Bouffard M, Chwalisz BK, Estrela T, Rizzo JF 3rd. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. Matched retrospective cohort from a single tertiary eye center: NAION incidence higher among semaglutide-prescribed patients vs non-GLP-1 comparators (HR 4.28 in T2D cohort; HR 7.64 in overweight/obesity cohort). First peer-reviewed signal; replications mixed; FDA + EMA both monitoring. JAMA Ophthalmol. 2024. PMID: 38958939.
6.He L, Wang J, Ping F, Yang N, Huang J, Li Y, Xu L, Li W, Zhang H. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. 76 RCTs, n=103,371: GLP-1 RA use associated with increased risk of gallbladder/biliary disease (relative risk 1.37 vs placebo); higher doses, longer durations, and weight-loss indications drove the signal more than glycemic-control indications. JAMA Intern Med. 2022. PMID: 35344001.
7.Woronow D, Chamberlain C, Niak A, Avigan M, Houstoun M, Kortepeter C. Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration. FAERS case-series analysis supporting the labeling addition for acute cholecystitis across the GLP-1 receptor agonist class. JAMA Intern Med. 2022. PMID: 36036939.
8.Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Electronic-health-record cohort of 240,618 overweight/obesity patients and 1,589,855 T2D patients: semaglutide associated with LOWER risk of suicidal ideation versus non-GLP-1 anti-obesity comparators (HR 0.27 in obesity cohort; HR 0.36 in T2D cohort). Counterpoint to the spontaneous-reporting suicidality signal. Nat Med. 2024. PMID: 38182782.
9.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). Reference for the magnitude of weight loss at semaglutide 2.4 mg that drives the gallbladder-disease signal in the long-term safety picture: mean -14.9% body weight at 68 weeks. N Engl J Med. 2021. PMID: 33567185.
10.Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. Patients who completed a 20-week semaglutide 2.4 mg titration were randomized to continued semaglutide or switched to placebo for 48 weeks. Continued group: additional -7.9% body weight from week 20 onward. Discontinued group: +6.9% body weight regain. Discontinuation-effects evidence base. JAMA. 2021. PMID: 33755728.
11.Novo Nordisk Inc. OZEMPIC (semaglutide) injection, for subcutaneous use — US Prescribing Information. §5 Warnings and Precautions and §6 Adverse Reactions cover post-marketing surveillance signals: thyroid C-cell tumors (boxed), acute pancreatitis, acute gallbladder disease, acute kidney injury secondary to dehydration, diabetic retinopathy complications, hypoglycemia with concomitant insulin or sulfonylurea, suicidal behavior and ideation (post-marketing), pregnancy (discontinue ≥2 months before planned pregnancy). FDA Approved Labeling (DailyMed NIH). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79

Glossary references

Key terms in this article, linked to their canonical definitions.

Ozempic · Drugs and brands
Semaglutide · Drugs and brands

Important disclaimer. This article is educational information only — not medical advice and not a substitute for consultation with a licensed prescriber. Ozempic is a prescription medication with a boxed warning, multiple contraindications, and active post-marketing surveillance signals. Every clinical decision involving Ozempic must be made with a licensed prescriber who has reviewed the full FDA prescribing information and the individual patient’s history. Every regulatory and trial claim in this article is anchored to a primary source (DailyMed or PubMed). Weight Loss Rankings does not prescribe, dispense, or endorse any specific medication or pharmacy.